Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.69 BRL | -1.17% | +4.32% | -50.29% |
Apr. 16 | UnitedHealth warns of $1.15-$1.35/share hit this year from hack | RE |
Mar. 22 | Transcript : Qualicorp Consultoria e Corretora de Seguros S.A., Q4 2023 Earnings Call, Mar 22, 2024 |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The company is one of the best yield companies with high dividend expectations.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The group shows a rather high level of debt in proportion to its EBITDA.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Multiline Insurance & Brokers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-50.29% | 92.33M | B+ | ||
+10.64% | 111B | B- | ||
+10.27% | 101B | C+ | ||
+4.76% | 97.8B | B | ||
+1.07% | 70.23B | C+ | ||
+9.82% | 19.6B | A- | ||
-4.04% | 12.49B | B- | ||
+10.18% | 11.22B | A- | ||
+9.70% | 10.57B | A | ||
+20.46% | 10.07B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- QUAL3 Stock
- Ratings Qualicorp Consultoria e Corretora de Seguros S.A.